213382-45-7

Usage

Uses

Used in Organic Synthesis:
5-bromo-4-fluoro-2-nitrobenzaldehyde is used as a key intermediate in the synthesis of pharmaceuticals and agrochemicals. Its distinct functional groups allow for further chemical reactions, enabling the production of a wide range of compounds with potential therapeutic and agricultural benefits.
Used in Material Development:
Due to its unique structure, 5-bromo-4-fluoro-2-nitrobenzaldehyde is utilized in the development of new materials. Its properties can be harnessed to create innovative materials with specific characteristics, such as improved stability or enhanced reactivity, for various industrial applications.
Used as a Precursor in Chemical Reactions:
5-bromo-4-fluoro-2-nitrobenzaldehyde serves as a precursor in various chemical reactions, allowing for the synthesis of complex organic compounds. Its presence in these reactions can facilitate the formation of desired products, making it an essential component in the synthesis process.
Used in Medical Research:
5-bromo-4-fluoro-2-nitrobenzaldehyde has been studied for its potential biological activities, including antimicrobial and antiviral properties. Its ability to exhibit these properties makes it a compound of interest for further research and potential applications in the medical industry, where it could contribute to the development of new treatments and therapies.
Used in Agricultural Research:
In addition to its potential medical applications, 5-bromo-4-fluoro-2-nitrobenzaldehyde has also been investigated for its possible use in the agricultural industry. Its antimicrobial properties could be harnessed to develop new pesticides or fungicides, contributing to more effective crop protection strategies and promoting sustainable agriculture.

Upstream product

• 77771-02-9 3-bromo-4-fluorobenzaldehyde 

Downstream Products

• 511257-14-0 2-[(E)-Benzyloxyimino]-3-[3-bromo-5-(2-bromo-4-formyl-5-nitro-phenoxy)-4-methoxy-phenyl]-propionic acid ethyl ester 
• 1020574-89-3 ethyl 6-bromo-7-fluoro-2-quinolinecarboxylate 
• 315188-30-8 2-amino-5-bromo-4-fluorobenzaldehyde 
• 1020574-83-7 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-7-fluoro-2-quinolinecarboxylic acid 
• 1020574-95-1 ethyl 7-fluoro-6-(4-hydroxyphenyl)-2-quinolinecarboxylate 
• 1020575-01-2 ethyl 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-7-fluoro-2-quinolinecarboxylate 
• 1609390-07-9 C₁₀H₁₀BrNO₅ 
• 1609389-87-8 C₁₁H₁₃BrN₂O₄ 
• 1319194-61-0 (2-(2-amino-7-fluoro-3-morpholinoquinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 

Relevant academic research and scientific papers

QUINAZOLINYL COMPOUNDS AND METHODS OF USE

Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4 and A are as defined herein. The present invention also relates to compos

BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS

The invention relates to novel bicyclic heterocycle derivatives of formula (I) wherein Cy1,Cy2, R1,R2 and L have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are usefulas bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

Elaboration of tetra-orthogonally-substituted aromatic scaffolds towards novel EGFR-kinase inhibitors

Nitration of three regioisomers of bromo-fluorobenzaldehyde proceeds regioselectively, notably with H2SO4/HNO3 at 0 °C. The thereby synthesized tetrasubstituted aromatics, endowed with orthogonal substituents, can be elabo

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

SELECTIVE HDAC1 AND HDAC2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).

2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)

The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and / or dementia. The compounds of the present invention are inhibitors of β-secretase, also known as β-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.